Initiation of the multi-target anti-neuroinflammatory drug minocycline within 72 hours of acute ischemic stroke had a significant benefit in functional outcome compared to placebo, with no increased ...

NCD Academy is an online platform designed to empower the global primary care community with the knowledge, tools, and skills required to effectively address and mitigate the leading risk factors of ...

Using the ACC's health equity strategy, we aim to achieve a culture of equitable cardiovascular care and heart health for all. The ACC is paving the road to health equity through advocacy, education, ...

Beta-blocker therapy following myocardial infarction (MI) was the primary focus of a hot line session at ESC Congress 2025. Study investigators presented findings from the REBOOT-CNIC and ...

Long-term melatonin use for insomnia was associated with a higher hazard of heart failure (HF), an increase in HF hospitalizations and a doubling of all-cause mortality over five years, according to a ...

Mavacamten did not significantly improve exercise capacity as assessed by peak oxygen uptake or improve patient-reported health status compared with placebo in patients with symptomatic nonobstructive ...

Food supplementation for patients following a heart failure (HF)-related hospitalization was both feasible and acceptable and associated with clinically meaningful improvement in quality of life ...

We are a young, vibrant section dedicated to adding value to Section members interested in Innovation across the cardiovascular spectrum. Our section is member-driven and focused on all aspects of ...

The newest clinical guideline released by the ACC and the American Heart Association (AHA) provides new and updated recommendations for preventing and optimally managing atrial fibrillation (AFib).

The U.S. Food and Drug Administration (FDA) has approved the FARAPULSE Pulsed Field Ablation System for isolation of pulmonary veins in the treatment of drug-refractory, recurrent, symptomatic, ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...

Findings from the PREVUE-VALVE study presented at TCT 2025 shed light on the prevalence of valvular heart disease (VHD) and its subtypes among older Americans, as well as the influence of age, sex, ...